The US FDA has approved 6 NDAs in Apr 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 26 novel products in 2022In Apr 2022, the major highlights drugs were Vivjoa for Recurrent Vulvovaginal Candidiasis, Cuvrior for Stable Wilson’s Disease, Igalmi for Acute Treatment of Agitation…